Kornimate/medical-research-clean huggingface dataset:
hyporesponsiveness of natural killer cells and a dysfunctional inflammatory response in critically ill patients

Conditions: Critical Illness

Summary: to investigate natural killer (nk) cell activities, circulating cytokine levels and peripheral blood mononuclear cell (pbmc) cytokine production status in critically ill patients.

blood samples were collected \< 24 hours after admission from 24 intensive care unit (icu) patients and 24 age-, sex-, and body mass index (bmi)-matched healthy controls. nk cell activities, cytokine concentrations and cytokine production by pbmcs and lipopolysaccharide (lps)-stimulated pbmcs were measured.

Eligibility criteria:
inclusion criteria: * icu patients * for healthy controls: nondiabetic and nonobese subjects exclusion criteria: * for healthy controls: diabetes; history/presence of significant metabolic disease; pregnancy or breast-feeding; acute or chronic infection; liver disease; kidney disease; gastrointestinal disease; subjects taking any drugs or supplements
effectiveness of the treatment for infant iron deficiency anemia by taking lactoferrin and ferralia

Conditions: Iron Deficiency Anemia

Summary: a multi-center,randomized,double-blind,controlled clinical trial was used to investigate the effectiveness of the treatment of infant iron deficiency anemia by taking ferralia and different contents lactoferrin.

5-9 months old infants with iron deficiency anemia were randomly divided into three groups. on the basis of giving the same dose of ferralia,three different levels lactoferrin infant formula were intervened 3 months respectively,and evaluate the clinical effect.

Eligibility criteria:
inclusion criteria: * full term,healthy infants at 37-42 weeks of gestational age * 5-9 months old infants were diagnose as iron deficiency anemia * accepting bottle feeding exclusion criteria: * hb\<60 g/l * other microcytic, hypochromic anemia
a study to evaluate ab308 in combination with ab122 in participants with advanced malignancies

Conditions: Advanced Solid Tumor; Non Small Cell Lung Cancer (NSCLC); Melanoma; Cervical Cancer; Multiple Myeloma; Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma (DLBCL); Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer

Summary: this is a phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (pk), pharmacodynamic (pd), and clinical activity of ab308 in combination with zimberelimab (ab122) in participants with advanced malignancies.


Eligibility criteria:
inclusion criteria: * capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol. * male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent. * contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * adequate organ and marrow function exclusion criteria: * history of trauma or major surgery within 28 days prior to the first dose of study treatment. * prior treatment with an anti-tigit antibody. * any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment. * prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment. * discontinued prior immunotherapy for immune related adverse events with a high severity. note: other protocol defined inclusion/exclusion criteria may apply.
the effectiveness of stretching and orthoses in individuals with carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the objective of this study is to compare the effectiveness of stretching and prefabricated orthoses versus orthoses alone in individuals with carpal tunnel syndrome (cts) using validated condition-appropriate outcome measures such as bctq, pain levels, grip strength, and nerve conduction studies.


Eligibility criteria:
inclusion criteria: 1. men and women aged 30-60 years or older with a confirmed diagnosis of carpal tunnel syndrome based on clinical presentation and/or nerve conduction studies. 2. participants must have a moderate level of symptom severity, defined as a score of 2 or greater on the symptom severity subscale of the boston carpal tunnel questionnaire (bctq). 3. participants must have a moderate level of functional impairment, defined as a score of 2 or greater on the functional status subscale of the bctq. 4. participants must be willing and able to provide informed consent to participate in the study. exclusion criteria: 1. participants with a history of hand or wrist surgery within the past 6 months, as this could impact hand function and confound the study results. 2. participants with severe hand or wrist pain that would prevent completion of the outcome measures or interfere with their ability to participate in the study. 3. participants with severe cognitive impairment or language barrier that would prevent understanding of the study instructions or interfere with their ability to participate in the study. 4. participants with any other medical condition that could affect hand function or interfere with test completion, such as rheumatoid arthritis, osteoarthritis, or peripheral neuropathy. 5. participants who have participated in any other clinical trial or research study involving the hand or wrist within the past 3 months, as this could impact hand function and confound the study results. 6. participants who are unable to comply with study procedures or follow-up requirements, such as attending scheduled study visits or completing study questionnaires.
effect of vigabatrin on brain blood flow and glucose metabolism

Conditions: Epilepsy; Epilepsy, Complex Partial

Summary: this study is designed to test the effects of vigabatrin (gamma-vinyl-gaba) an experimental drug used for the treatment of epilepsy. the study will use positron emission tomography (pet scan) to detect areas of the brain receiving increased blood flow and using increased amounts of glucose. increases in blood flow and glucose use are good indicators of brain activity. researchers are interested in determining the effects of vigabatrin on brain blood flow and glucose use.

this double-blind placebo-controlled parallel design protocol will investigate the effects of gamma-vinyl-gaba (vigabatrin--gvg) an experimental antiepileptic drug, on cerebral glucose metabolism (lcmrglc), blood flow (cbf), and seizure frequency, in patients with uncontrolled complex partial (cps) and secondary generalized seizures (gtcs). positron emission tomography (pet) will be used to measure cbf and lcmrglc.

Eligibility criteria:
localization-related epilepsy. uncontrolled seizures. ability to tolerate tegretol monotherapy. no systemic illness requiring drug therapy. no illness that might be made worse by vigabatrin.

Keywords: cerebral metabolism complex partial seizures epilepsy
optimal blood sampling site for point of care lactate assessment

Conditions: Blood Lactic Acid Increased; Hip Fractures

Summary: the study was to compare blood lactate levels between ear lobe and finger against venous forearm blood sample using the electronic hand held lactate device in hip fracture patients with good cognitive function (amt \>/= 7)

following a hip fracture, surgical treatment is advocated to improve pain and mobility. most patients are elderly and a majority of them are frail. current best practice tariff and national institute for health and care excellence guidelines recommends that all those patients who undergo an operation should be performed within 36 hours from the time of injury to optimise recovery and function. the patients need to be medically optimised to undergo a major operation to have their hip fracture fixed. the adequacy of resuscitation is monitored by several clinical and biochemical markers. one of the important markers of resuscitation is serum lactate levels. this is used routinely in polytrauma patients. (moran and forward, 2012) the initial interest in lactate in hip fracture patients was based on the philosophy that a hip fracture in a frail elderly patient may be equivalent to a polytrauma in a young fit patient. subsequently, high serum lactate levels on admission in hip fracture patients have been shown to be associated with higher mortality1. however, at present, this is not routinely monitored in hip fracture patients. measurement of serum lactate levels presents logistics difficulties, as the blood sample has to be taken to an analyser and analysed within 20 minutes. hence the investigators want to use a point of care electronic hand held device - the lactate pro 2. the investigators have already tested this device against the laboratory analysers and it has been proven to be accurate. however in preliminary testing the investigators found a significant difference between fingertip and earlobe samples in volunteers. the volunteers do not represent our population of interest, which are hip fracture patients. the investigators aim is to determine which sample site; earlobe or fingertip, for lactate pro 2 testing best matches venous forearm samples upon which the association of higher mortality with high lactate was based. any risk to the patients participating in this study would be very small. the inclusion criteria to participate in this research study is a patient who has had a recent hip fracture awaiting surgery with a mental test score of 7/10 or above and is able to consent.

Eligibility criteria:
inclusion criteria: * male or female, aged 18 years or above. * diagnosed with an acute hip fracture. * have a mental test score of 7/10 or greater on assessment during admission. * participant is willing to consent to the study. exclusion criteria: * the participant will not enter the study if 1. there are injuries other than isolated hip fracture 2. age \<18 years 3. they are not willing to consent for the study 4. they have a mental test score less than 7/10 at the time of admission.

Keywords: blood lactate earlobe sample finger prick sample
vancomycin study in multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: the overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (ms). the gut microbiome plays an important role in autoimmunity, including ms. however, the identity of gut microbes modulating neuroinflammation in ms and their mechanisms of action remain obscure. hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain mri lesions in ms patients.


Eligibility criteria:
inclusion criteria: * aged 18 - 50 * newly diagnosed ms (2017 mcdonald criteria), cis or ris patients, who have experienced symptoms no earlier than the past year * treatment naive * able to understand the risks, benefits, and alternatives of participation and give meaningful consent exclusion criteria: * antibiotic use within the past 90 days; * pre- or probiotic use within past month or corticosteroids use within the past month; * use of tobacco products within the past 1 month; * history of treatment with immunosuppressants; * history of gastroenteritis within the past month or diagnosis with a chronic infectious disease, i.e. hepatitis b, c or hiv; * pregnancy or less than 6 months postpartum; * irritable bowel syndrome and other bowel dysfunction such as constipation; * history of bowel surgery; * inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, diabetes and any other auto-immune illness; * diagnosis with another neurological disease, behavioral or psychiatric conditions that would be incompatible with a safe and successful participation in the study (such as severe major depression, schizophrenia and presence of psychotic symptoms); * eating disorders such as anorexia nervosa, bulimia, or binge eating syndrome; * travel outside of the country within the past month; * contraindication to vancomycin including estimated glomerular filtration rate of \<60ml/min, impaired hearing or known allergy. * contraindication to mri such as implanted metallic objects

Keywords: gut microbiome peripheral immune function neuroinflammation gut-brain axis
parasternal block and tens for cardiac surgery

Conditions: Postoperative Pain

Summary: the objective of the present study was to compare the efficacy of tens and parasternal block with local anesthetic infiltration in relieving pain during the first 24 h period following median sternotomy.

patients experiencing pain after undergoing cardiac surgery may also experience prolonged immobilization, insufficient respiratory functions and the inability to cough due to median sternotomy. invasive and noninvasive interventions such as epidural analgesia, local regional blockade and the use of intravenous (iv) opioids, are used for postoperative pain management. transcutaneous electrical nerve stimulation (tens) is a noninvasive technique that is effective for postoperative pain management. it has been demonstrated to produce effective analgesia and reduce postoperative opioid requirements in patients undergoing cardiac surgery, and it has no side effects. parasternal local anesthetic infiltration around the sternum has been demonstrated to be useful in providing early postoperative analgesia, reducing opioid requirements and, therefore, producing a potential positive effect on recovery. the present prospective, randomized controlled study included 120 patients, 18 to 65 years of age, who were scheduled for elective valve repair or coronary artery bypass graft (cabg) surgery with cardiopulmonary bypass. a random number table was used to randomly allocate patients to one of three treatment groups to relieve postoperative pain during the first 24 h following median sternotomy: parasternal block group (parasternal block combined with levobupivacaine infiltration and pca(patient controlled analgesia)); tens group (tens and pca); or the control group (pca alone).

Eligibility criteria:
inclusion criteria: * 18 to 65 years of age, * who were scheduled for elective valve repair or coronary artery bypass graft (cabg) surgery with cardiopulmonary bypass exclusion criteria: * previous sternotomy for cabg or heart valve surgery; emergency surgery * ejection fraction \<40% * congestive heart failure * an allergy to amide-based local anesthetics, opioids or benzodiazepines * inability to provide informed consent * prolonged cardiopulmonary bypass time (\>145 min) * previous experience with tens

Keywords: postoperative pain parasternal block sternotomy tens
the change of cholesterol efflux capacity and coronary artery disease in real clinical practice

Conditions: Coronary Artery Disease; Cardiovascular Mortality; Myocardial Infarction; Stroke

Summary: the purpose of this study is to investigate the change of cholesterol efflux capacity in patients with coronary artery disease treated with secondary prevention drugs, and the correlation with the prognosis.

in this clinical trial, serum samples and associated clinical data of patients with coronary artery disease were collected from department of cardiology of lu'an shili hospital and the first affiliated hospital of jinan university. blood samples collected from all the participants at baseline (prior to the follow-up) and the time points of follow-up were placed into ordinary test tubes and stored at 4°c for less than 4 hours. the blood was then centrifuged, and serum was separated and stored at -80°c. the change of cholesterol efflux capacity, hdl-c subclasses (preβ1-hdl, hdl2, hdl3), the concentration and activity of plasma lcat were measured. a follow-up form was designed according to the research purpose and discussed among the team members. the follow-up was performed through telephone by the trained investigators with good communication skills and knowledge on the diagnosis and treatment of coronary artery disease. patients were followed up every six months from the day of discharge. the results of the follow-up were entered into the database, a process that was carried out by a designated person and double-checked by an independent person. the primary clinical endpoints were composite atherosclerotic cardiovascular disease outcomes, defined as nonfatal myocardial infarction, nonfatal stroke, or cardiovascular mortality. secondary clinical endpoints were revascularization, including percutaneous coronary intervention and coronary artery bypass grafting, and class iv heart failure requiring hospitalization.

Eligibility criteria:
inclusion criteria: signed informed consent; first diagnosis of cad through cag; aged 30-70. exclusion criteria: patients with severe liver or kidney damage; taking statins within the last 3 months; patients who had been diagnosed with cad and treated with oral medication; chronic diseases of the blood system; familial hyperlipidemia patients; patients combining autoimmune disease; patients combining acute infectious disease; patients who undertaken surgery or injury; patients who combining cancer; patients who taking glucocorticoid replacement therapy.
defining the role of the gut microbiome in mediating the effects of obesity on intestinal stem cells

Conditions: Obesity

Summary: new studies are revealing how a high-fat diet could be making the cells of the intestinal lining more likely to become cancerous. the investigators would like to study how obesity influences growth of intestinal stem cells, which could then trigger intestinal tumors. the investigators are proposing a pilot study of 20 subjects (comprised of 10 participants from each of two different bmi categories: 20-25 and 35 \& above), who will be asked to provide blood, stool, \& urine samples, undergo a flexible sigmoidoscopy, and complete food frequency questionnaires

hypothesis: the investigators will test the hypothesis that the gut microbiome drives many of the effects that a pro-obesity high-fat diet has on intestinal stem cell (isc) biology, which includes 1) an increase in isc numbers and proliferation, 2) a reduced dependency on niche cells for intestinal organoid initiation, or 3) the acquisition of organoid-initiation by non-stem cell population in the intestinal epithelium. specific aims: 1. to determine whether differences in the gut microbiome in obese human subjects correlates with enhanced intestinal stem cell numbers and function. 2. to validate whether obesity-driven changes in the gut microbiome of human recapitulate the effects of obesity on intestinal stem cell function in germ-free mice.

Eligibility criteria:
subject and control inclusion criteria 1. participants have a body mass index (bmi) between 20-25 or 35 and above. 2. adults aged 18-65 exclusion criteria: 1. known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or other inflammatory conditions or diabetes mellitus 2. antibiotic use within the past 4 weeks (they can be enrolled after a four week washout period and subsequent use during the 6 month study duration does not exclude them) 3. bowel preparation for colonoscopy within the past week 4. significant bowel surgery other than hysterectomy or appendectomy 5. pregnancy or plans to become pregnant within the study time frame 6. any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes. 7. age\<18 or vulnerable adults -

Keywords: intestinal stem cells
mis milif versus open

Conditions: Chronic Low Back Pain; Leg Pain

Summary: this study is being undertaken to compare the clinical outcomes of patients that have unilateral posterolateral lumbar interbody fusion using a traditional open approach versus the milif procedure based on the micor precision bone allograft, specialized atavi instrumentation, and minimally invasive visualization capabilities.

this is a prospective, multi-center, non-randomized cohort design clinical study to evaluate the clinical outcomes of patients that have a minimally invasive lumbar interbody fusion (milif) through the atavi system compared to traditional unilateral open lumbar interbody fusion through a midline incision. the study will involve up to approximately 12 investigational sites and enroll up to 126 patients.

Eligibility criteria:
inclusion criteria: * patient is between 18 and 75 years of age * patient is scheduled for an elective spinal lumbar interbody single level fusion * patient is a candidate for posterior unilateral lumbar fusion through a midline incision * indication for surgery and dominant symptom of chronic low back and/or leg pain * diagnosis of one or more of the following: * primary symptomatic degenerative disc disease confirmed with appropriate imaging studies and/or positive lumbar discography * spondylolisthesis grade i/ii * the affected motion segment reside in l2-s1 and are adjacent segments * patient, or authorized representative, signs a written informed consent form to participate in the study, prior to any study mandated determinations or procedure. exclusion criteria: * patient has a known fracture in the lumbar spine * patient has systemic infection or evidence of any surgical site infection (superficial or organ space) * patient has compromised immune system or autoimmune disease (wbc\ 20,000) * patient has uncontrolled diabetes * patient has a known malignancy * prior lumbar fusion attempt; prior laminectomy and/or discectomy are allowed * known medical or anatomical condition that would preclude a posterior lumbar fusion using metallic instrumentation (e.g., severe osteopenia) * patient with a planned placement of an electric bone stimulator * patient with a planned placement of indwelling epidural catheter for a long term pain management * patient is pregnant or wishes to become pregnant during the length of the study participation * patient is currently in litigation * patient is not likely to comply with the follow-up evaluation schedule * patient is participating in a clinical trial of another investigational drug or device.

Keywords: mis minimally invasive atavi flex posure retractor patients with chronic low back and/or leg pain who are candidates for elective lumbar interbody fusion through a posterior unilateral approach, for inclusion in the study. if the patient meets all of the eligibility criteria, they will be enrolled into the study and have either the milif or open procedure depending on the surgeon they present to (i.e., what group their surgeon agreed to participate in.)